687 related articles for article (PubMed ID: 14652817)
21. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
22. 'Pseudomesotheliomatous' carcinomas of the pleura: a 10-year analysis of cases from the Environmental Lung Disease Research Group, Cardiff.
Attanoos RL; Gibbs AR
Histopathology; 2003 Nov; 43(5):444-52. PubMed ID: 14636270
[TBL] [Abstract][Full Text] [Related]
23. Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura.
González-Lois C; Ballestín C; Sotelo MT; López-Ríos F; García-Prats MD; Villena V
Histopathology; 2001 Jun; 38(6):528-34. PubMed ID: 11422496
[TBL] [Abstract][Full Text] [Related]
24. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
Comin CE; Saieva C; Messerini L
Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical staining for bcl-2 and mcl-1 in intrathyroidal epithelial thymoma (ITET)/carcinoma showing thymus-like differentiation (CASTLE) and cervical thymic carcinoma.
Dorfman DM; Shahsafaei A; Miyauchi A
Mod Pathol; 1998 Oct; 11(10):989-94. PubMed ID: 9796728
[TBL] [Abstract][Full Text] [Related]
26. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma.
Miettinen M; Limon J; Niezabitowski A; Lasota J
Am J Surg Pathol; 2001 May; 25(5):610-7. PubMed ID: 11342772
[TBL] [Abstract][Full Text] [Related]
27. Calretinin-expressing lung adenocarcinoma: Distinct characteristics of advanced stages, smoker-type features, and rare expression of other mesothelial markers are useful to differentiate epithelioid mesothelioma.
Matsuda M; Ninomiya H; Wakejima R; Inamura K; Okumura S; Mun M; Kitagawa M; Ishikawa Y
Pathol Res Pract; 2020 Mar; 216(3):152817. PubMed ID: 32008868
[TBL] [Abstract][Full Text] [Related]
28. Application of immunohistochemistry to the diagnosis of malignant mesothelioma.
Marchevsky AM
Arch Pathol Lab Med; 2008 Mar; 132(3):397-401. PubMed ID: 18318582
[TBL] [Abstract][Full Text] [Related]
29. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas.
Ordóñez NG
Am J Surg Pathol; 1998 Oct; 22(10):1203-14. PubMed ID: 9777982
[TBL] [Abstract][Full Text] [Related]
30. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma.
Leers MP; Aarts MM; Theunissen PH
Histopathology; 1998 Mar; 32(3):209-16. PubMed ID: 9568505
[TBL] [Abstract][Full Text] [Related]
31. Expression of calretinin by breast carcinoma and the potential for misdiagnosis of mesothelioma.
Powell G; Roche H; Roche WR
Histopathology; 2011 Nov; 59(5):950-6. PubMed ID: 22092406
[TBL] [Abstract][Full Text] [Related]
32. The MIC2 antibody 013. Practical application for the study of thymic epithelial tumors.
Chan JK; Tsang WY; Seneviratne S; Pau MY
Am J Surg Pathol; 1995 Oct; 19(10):1115-23. PubMed ID: 7573670
[TBL] [Abstract][Full Text] [Related]
33. Spindle cell thymomas: an immunohistochemical study of 30 cases.
Weissferdt A; Hernandez JC; Kalhor N; Moran CA
Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):329-35. PubMed ID: 21386704
[TBL] [Abstract][Full Text] [Related]
34. Thymic carcinomas, but not thymomas and carcinomas of other sites, show CD5 immunoreactivity.
Dorfman DM; Shahsafaei A; Chan JK
Am J Surg Pathol; 1997 Aug; 21(8):936-40. PubMed ID: 9255257
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study.
Ordóñez NG; Sahin AA
Hum Pathol; 2014 Jul; 45(7):1529-40. PubMed ID: 24816068
[TBL] [Abstract][Full Text] [Related]
36. Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours.
Pan CC; Chen PC; Wang LS; Lee JY; Chiang H
Histopathology; 2003 Aug; 43(2):165-72. PubMed ID: 12877732
[TBL] [Abstract][Full Text] [Related]
37. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
Brown RW; Clark GM; Tandon AK; Allred DC
Hum Pathol; 1993 Apr; 24(4):347-54. PubMed ID: 7684019
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic utility of thymic epithelial markers CD205 (DEC205) and Foxn1 in thymic epithelial neoplasms.
Nonaka D; Henley JD; Chiriboga L; Yee H
Am J Surg Pathol; 2007 Jul; 31(7):1038-44. PubMed ID: 17592270
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms.
Kojika M; Ishii G; Yoshida J; Nishimura M; Hishida T; Ota SJ; Murata Y; Nagai K; Ochiai A
Mod Pathol; 2009 Oct; 22(10):1341-50. PubMed ID: 19648882
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies.
Abutaily AS; Addis BJ; Roche WR
J Clin Pathol; 2002 Sep; 55(9):662-8. PubMed ID: 12194995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
